• Sunshine Biopharma posted a net loss of $1.24 million, or $0.25 per share, for quarter ended March 31, 2026, versus a net loss of $1.18 million, or $0.44 per share, a year earlier.
• Net sales fell 9.1% to $8.09 million, with gross profit down to $2.18 million.
• Operating loss widened to $1.4 million as general and administrative expense eased to $3.58 million.
• Cash and cash equivalents totaled $6.91 million at quarter-end; net cash used in operating activities increased to $2.07 million.
• Company said it is generating about $8 million in quarterly revenue with a quarterly deficit of about $1.2 million, expecting cash on hand and cash from sales to fund operations for next 17 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-003819), on May 13, 2026, and is solely responsible for the information contained therein.